Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
Conditions: Prostate Cancer

Interventions: Drug: Docetaxel; Drug: ADT; Drug: Abiraterone

Sponsors: Northwestern University; National Cancer Institute (NCI)

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 30, 2023Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments